Table 1.
Patient characteristics
| Characteristics | Discovery | Verification | ||||||
|---|---|---|---|---|---|---|---|---|
| Sclerotic chronic GVHD* | Chronic GVHD with IST† | Chronic GVHD without IST† | BOS‡ | No chronic GVHD | Sclerotic chronic GVHD | Nonsclerotic chronic GVHD | No chronic GVHD | |
| Total no. | 21 | 16 | 11 | 6 | 20 | 62 | 62 | 62 |
| Median age at transplant (range), y | 51 (26-70) | 50 (18-63) | 42 (24-60) | 42 (35-61) | 44 (20-68) | 53 (16-74) | 52 (29-74) | 51 (22-74) |
| Sex, n (%) | ||||||||
| Male | 10 (48) | 10 (63) | 5 (45) | 3 (50) | 10 (50) | 32 (52) | 32 (52) | 32 (52) |
| Female | 11 (52) | 6 (38) | 6 (55) | 3 (50) | 10 (50) | 30 (48) | 30 (48) | 30 (48) |
| Race, n (%) | ||||||||
| White | 18 (86) | 13 (81) | 10 (91) | 6 (100) | 19 (95) | 58 (94) | 56 (90) | 53 (85) |
| Others | 3 (14) | 3 (19) | 1 (9) | 0 (0) | 1 (5) | 4 (6) | 6 (10) | 9 (15) |
| Primary diagnosis, n (%) | ||||||||
| Acute leukemia | 8 (38) | 6 (38) | 5 (45) | 1 (17) | 11 (55) | 31 (50) | 29 (47) | 31 (50) |
| Chronic leukemia | 0 (0) | 2 (13) | 0 (0) | 2 (33) | 0 (0) | 5 (8) | 8 (13) | 7 (11) |
| MDS/MPN | 6 (29) | 2 (13) | 1 (9) | 0 (0) | 2 (10) | 9 (15) | 12 (19) | 11 (18) |
| Lymphoma | 5 (24) | 4 (25) | 4 (36) | 2 (33) | 5 (25) | 12 (19) | 7 (11) | 8 (13) |
| Others | 2 (10) | 2 (13) | 1 (9) | 1 (17) | 2 (10) | 5 (8) | 6 (10) | 5 (8) |
| Stem cell source, n (%) | ||||||||
| Peripheral blood stem cell | 20 (95) | 13 (81) | 8 (73) | 6 (100) | 13 (65) | 58 (94) | 56 (90) | 48 (77) |
| Bone marrow | 1 (5) | 2 (13) | 1 (9) | 0 (0) | 7 (35) | 3 (5) | 5 (8) | 10 (16) |
| Cord blood | 0 (0) | 1 (6) | 2 (18) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 4 (6) |
| Missing | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) |
| Conditioning intensity, n (%) | ||||||||
| Myeloablative | 15 (71) | 8 (50) | 6 (55) | 2 (33) | 11 (55) | 33 (53) | 25 (40) | 38 (61) |
| Reduced intensity | 6 (29) | 8 (50) | 5 (45) | 4 (67) | 9 (45) | 29 (47) | 37 (60) | 24 (39) |
| Donor type, n (%) | ||||||||
| HLA-matched relative | 12 (57) | 5 (31) | 5 (45) | 1 (17) | 13 (65) | 23 (37) | 19 (31) | 26 (42) |
| HLA-mismatched relative | 1 (5) | 1 (6) | 0 (0) | 0 (0) | 3§ (15) | 0 (0) | 3 (5) | 4§ (6) |
| Unrelated donor | 8 (38) | 10 (63) | 6 (55) | 5 (83) | 4 (20) | 39 (63) | 40 (65) | 32 (52) |
| Female donor to a male recipient, n (%) | 4 (19) | 6 (38) | 3 (27) | 2 (33) | 2 (10) | 12 (19) | 14 (23) | 11 (18) |
| Prior grade 2-4 acute GVHD, n (%) | 13 (62) | 15 (94) | 8 (73) | 4 (67) | 8 (40) | 26 (42) | 44 (71) | 38 (61) |
| Median time from HCT to sample draw (range), mo | 12 (2-41) | 2.8 (2.6-7.6) | 11 (7-12) | 13 (11-26) | 12 (11-13) | 29 (8-55) | 29 (8-58) | 13 (9-64) |
| Median time from chronic GVHD to sample draw (range), mo | 0 (0-37) | 0 (0-0) | 0 (0-0.1) | 2.9 (0-15) | NA | 11 (0.1-45) | 17 (0.5-53) | NA |
| Steroid treatment at sample draw, n (%) | 5 (24) | 13 (81) | 0 (0) | 5 (83) | 0 (0) | 54 (87) | 33 (53) | 0 (0) |
BOS, bronchiolitis obliterans syndrome; IST, immunosuppressive treatment; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm.
*
Without BOS.
†
Without sclerosis or BOS.
‡
Without sclerosis.
§
Among these patients, 3 in the discovery cohort and 2 in the verification cohort had HLA-haploidentical donors.